Drive TKI drugs. Although the PFS Tenofovir Viread is associated with mTOR-targeting agents modest effect in the first line in patients with good or intermediate risk is still not completely Characterized ndig. These drugs are generally more active in patients treatmentna’ve and criteria for their use, to a large extent still empirical. Determine the optimal dose, dosing schedule, the sequence of treatment for individual patients, and how to combine these and other agents directed to detection of other molecular mechanisms relevant to RCC in several studies. Clinical applications of circulating biomarkers in advanced RCC biomarkers show significant clinical manifestations, such as the development of cancer, recurrence, progression or death of the patient and can beused risk assessment, screening, diagnosis, prognosis, profit prediction of specific therapies and assessment of recurrence or progression of the disease .
Prognostic factors for diseases associated natural history, independent Ngig them, Including Therapy Lich risk of occurrence of the disease, relapse, progression or survival. Pr Predictive marker for patients who experience varying Ma S benefit, so that identification of individualized therapy with maximum benefit and minimal risk of specific treatments or class of related therapies. Randomized clinical trials that will use a treatment group or comparison groups generally required to report as pr Diktiver marker. If no comparator is, as in the single-arm studies, the markers only at, together with a clinical benefit, because it does not m3 is possible to know whether the marker is forecast, forecast, or both for intervention. Or pharmacodynamic markers of activity t to evaluate the biological activity of t expect a drug, what the effects of the tumor or tissue replacement, with or without correlation with the concentration of the drug or clinical benefit. The following sections review the recent progress in the L Soluble and cellular markers in the blood Ren targeted therapies in advanced RCC. Prognosis L Soluble biomarkers in RCC, as in many other solid tumors, the first attempts to predict the outcome in the different clinical features patient focus.
Several prognostic models, clinical parameters, the characteristics of patients survive with the associated results to identify which established the variable natural history of metastatic renal cell carcinoma, independent Ngig of the treatment. The anti-angiogenesis therapy-induced toxicity was t also investigated. In particular, the development of hypertension treated with strong clinical outcomes in patients with metastatic renal cell carcinoma associated with various VEGF inhibitors. However, until the biological determinants of this reaction are well defined and its development alternatives will be used t happy that w During the treatment, the clinical value of high blood pressure as a marker of clinical benefit of targeted therapy VEGF limited. The analysis of the VHL mutation status in CCRCC have provided inconsistent data available to support its value as either a prognostic or pr Predictive. Responsive to the state of activation of HIF-subunits and several HIF genes are currently being examined. A target of HIF, VEGF and other factors associated with angiogenesis and Tumorigenit t in serum or plasma have been evaluated in several clinical trials with targeted agents.